Patient info Open main menu

Propoven 1% emulsion for injection/infusion in Pre-filled syringe – patient leaflet, side effects, dosage

Last updated: · Text from the MHRA, as of · About this document

Medicine status: Prescription only (POM) Details

Medicine strength:
1% (10 mg/ml)
Contains active substance:
ATC code:

Patient leaflet - Propoven 1% emulsion for injection/infusion in Pre-filled syringe

1. What Propofol 1% is and what it is used for

Propofol 1% belongs to a group of medicines called ‘general anaesthetics’. General anaesthetics are used to cause unconsciousness (sleep) so that surgical operations or other procedures can be performed. They can also be used to sedate you (so that you are sleepy but not completely asleep).

Propofol 1% is used to:

  • induce and maintain general anaesthesia in adults, adolescents and children older than 1 month.
  • sedate patients older than 16 years of age receiving artificial respiration in intensive care.
  • sedate adults, adolescents and children older than 1 month during diagnostic and surgical procedures, alone or in combination with local or regional anaesthesia.

2. What you need to know before you are given Propofol 1%

Do not use Propofol 1%

  • if you are allergic to propofol, soya, peanut or any of the other ingredients of this medicine (listed in section 6).
  • in patients of 16 years of age or younger for sedation in intensive care.

Warnings and precautions

Talk to your doctor, pharmacist or nurse before you are given Propofol 1% and if any of the subsequent mentioned applies to you or applied to you in the past.

You should not receive Propofol 1% , or only under extreme caution and intensive monitoring, if you:

  • have advanced heart failure
  • have any other serious disease of the heart
  • are receiving electroconvulsive therapy (ECT, a treatment for psychiatric problems)

In general, Propofol 1% should be given with caution to elderly or weak patients.

Before receiving Propofol 1%, tell your anaesthetist or intensive care doctor if you have:

  • heart disease
  • lung disease
  • kidney disease
  • liver disease
  • seizures (epilepsy)
  • a raised pressure inside the skull (raised intracranial pressure). In combination with low blood pressure the amount of blood reaching the brain may be decreased.
  • altered levels of fat in the blood. If you are receiving total parenteral nutrition (feeding through a vein), the levels of fat in your blood must be monitored.
  • if your body has lost lots of water (you are hypovolaemic).

If you have any of the following conditions, they must be treated before you receive Fresenius Propofol:

  • heart failure
  • when there is insufficient blood reaching the tissues (circulatory failure)
  • severe breathing problems (respiratory failure)
  • dehydration (hypovolaemia)
  • seizures (epilepsy)

Propofol 1% may increase the risk of

  • epileptic seizures
  • a nervous reflex that slows the heart rate (vagotonia, bradycardia)
  • changes in the blood flow to the organs of the body (haemodynamic effects on the cardiovascular system) if you are overweight and receive high doses of Propofol 1%.

Involuntary movements can occur during sedation with Propofol 1%. The doctors will take into account how this might affect surgical procedures being performed under sedation and will take the necessary precautions.

Very occasionally, after anaesthesia, there may be a period of unconsciousness associated with stiffness of the muscles. This requires observation by the medical staff but no other treatment. It will resolve spontaneously.

The injection of Propofol 1% can be painful. A local anaesthetic can be used to reduce this pain but can have its own side effects.

You will not be allowed to leave the hospital until you are fully awake. If you are able to go home shortly after receiving propofol you should not go home unaccompanied.

Children and adolescents

The use of Propofol 1% is not recommended for use in new-born infants or children younger than 1 month.

Due to the limited data available, the use of target controlled infusion (TCI) in the paediatric population below 2 years of age cannot be recommended. Propofol 1% must not be given to children and adolescents younger than 16 years of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient group for this indication.

Other medicines and Propofol 1%

Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.

In particular, tell your doctor, anaesthetist or nurse if you are taking any of the following medicines:

  • Rifampicin (for tuberculosis – TB).
  • Midazolam (used to induce sedation (a very relaxed state of calm, drowsiness or sleep) and relieves anxiety and muscle tension).

You must take special care if you are also taking/ receiving any of the following medicines:

  • Premedications (your anaesthetist will know which medicines can be influenced by Propofol 1%)
  • Other anaesthetics, including general, regional, local and inhalational anaesthetics (Lower doses of Propofol 1% may be required. Your anaesthetist will know this.)
  • Painkillers (analgesics)
  • Strong painkillers (fentanyl or opioids)
  • Parasympatholytic agents (medicines used to treat e.g. painful cramps of organs, asthma or Parkinson’s disease)
  • Benzodiazepines (medicines used to treat anxiety)
  • Suxamethonium (muscle relaxant)
  • Drugs that affect many of the internal body functions such as the heart rate, e.g. atropine
  • Alcohol containing medicines or beverages
  • Neostigmine (medicine used to treat a disease called myasthenia gravis)

The following information is intended for healthcare professionals only:

Propofol 1% should not be mixed prior to administration with injection or infusion solutions other than glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9 %) solution for injection or preservative free lidocaine 10 mg/ml (1 %) solution for injection. Final propofol concentration must not be below 2 mg/ml.

For single use only. Any unused emulsion must be discarded.

Pre-filled syringes should be shaken before use. If two layers can be seen after shaking the emulsion should not be used.

Use only homogeneous preparations and undamaged pre-filled syringes.

After use, tapped pre-filled syringes must be discarded.

Propofol should be given by those trained in anaesthesia (or, where appropriate, doctors trained in the care of patients in Intensive Care). Patients should be constantly monitored and facilities for maintenance of a patent airway, artificial ventilation, oxygen enrichment and other resuscitative facilities should be readily available at all times. Propofol should not be administered by the person conducting the diagnostic or surgical procedure.

M0xxxxx/00 UK/IE Propofol 1% (10 mg/ml) emulsion for injection/infusion in pre-filled syringe

Propofol

Abuse of, and dependence on propofol, predominantly by health care professionals, have been reported. As with other general anaesthetics, the administration of propofol without airway care may result in fatal respiratory complications.

When propofol is administered for conscious sedation, for surgical and diagnostic procedures, patients should be continually monitored for early signs of hypotension, airway obstruction and oxygen desaturation.

Propofol 1% may be administered undiluted or diluted in glucose 50 mg/ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9 %) solution for injection.

Propofol 1% must not be mixed with any other solutions for infusion or injection except those mentioned above. Glucose 50 mg/ml (5 %) solution for injection, sodium chloride 9 mg/ml (0.9 %) solution for injection or sodium chloride 1.8 mg/ml (0.18 %) solution for injection and glucose 40 mg/ ml (4 %) solution for injection may be given through the same infusion set.

Co-administration of other medicinal products or fluids added to the Propofol 1% infusion line must occur close to the cannula site using a Y-piece connector or a three-way valve.

Propofol 1% is a lipid containing emulsion without antimicrobial preservatives and may support rapid growth of microorganisms.

  • Cyclosporine (medicine used to prevent transplant rejections)
  • Valproate (medicine used to treat epilepsy or mental disorders)

Propofol 1% with food, drink and alcohol

After you have been given Fresenius Propofol 1%, you should not eat, drink or consume alcohol until fully recovered.

Pregnancy and breastfeeding

If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

Propofol 1% should not be given to pregnant women unless clearly necessary. You should stop breast-feeding and discard any breast milk for 24 hours after receiving Fresenius Propofol 1%.

Driving and using machines

After having propofol you may still feel sleepy for some time. Do not drive or use any tools or machines until you are sure the effects have worn off.

If you are able to go home shortly after receiving Propofol, do not drive a car or go home unaccompanied.

Ask your doctor when you can start doing these activities again and when you can go back to work.

Propofol 1% contains soya-bean oil and sodium

Propofol 1% contains soya-bean oil. If you are allergic to peanut or soya, do not use this medicinal product.

This medicinal product contains less than 1 mmol (23 mg) sodium per 100 ml, i.e. essentially ´sodium-free`.

3. How to use Propofol 1%

Propofol 1% will only be given to you in hospitals or suitable therapy units by, or under the direct supervision of your anaesthetist or intensive care doctor.

Dosage

The dose you are given will vary depending on your age, body weight and physical condition. The doctor will give the correct dose to start and to sustain anaesthesia or to achieve the required level of sedation, by carefully watching your responses and vital signs (pulse, blood pressure, breathing, etc).

You may need several different medicines to keep you asleep or sleepy, free from pain, breathing in a healthy way and to keep your blood pressure steady. The doctor will decide which medicines you need and when you need them.

Adults

Most people need 1.5 - 2.5 mg propofol per kg body weight to make them go to sleep (induction of anaesthesia), and then 4 to 12 mg propofol per kg body weight per hour after this to keep them asleep (maintenance of anaesthesia). For sedation, doses of 0.3 to 4.0 mg propofol per kg body weight per hour are usually sufficient.

For sedation during surgical and diagnostic procedures in adults, most patients will require 0.5 - 1 mg propofol per kg body weight over 1 to 5 minutes for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol 1% infusion to the desired level of sedation. Most patients will require 1.5 - 4.5 mg propofol per kg body weight per hour. The infusion may be supplemented by bolus administration of 10 - 20 mg propofol (1 - 2 ml Propofol 1% 10 mg/ml) if a rapid increase of the depth of sedation is required.

To provide sedation for ventilated patients older than 16 years of age under intensive care conditions the dose will be adjusted according to the depth of sedation required. Usually satisfactory sedation is achieved by continuous infusion with administration rates in the range of 0.3 to 4.0 mg propofol per kg body weight per hour. Rates of infusion greater than 4.0 mg propofol per kg bodyweight per hour are not recommended.

Elderly and weak patients

Elderly and weak patients may require lower doses.

Use in children and adolescents over one month of age

The use of Propofol 1% is not recommended in children younger than 1 month.

Special care should also be observed when administering Propofol 1% to children less than 3 years of age. However, evidence now available does not suggest that this is any less safe than in children older than 3 years.

The dose should be adjusted according to age and/or body weight. Most patients over 8 years of age require approximately 2.5 mg/kg bodyweight Propofol 1% to make them go to sleep (induction of anaesthesia). In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher (2.5 - 4 mg/kg bodyweight).

Rates in the region of 9 - 15 mg/kg/h usually achieve satisfactory anaesthesia to keep them asleep (maintenance of anaesthesia). In younger children, especially between the age of 1 month and 3 years, dose requirements may be higher.

For sedation during surgical and diagnostic procedures in children over 1 month of age with Propofol 1% most paediatric patients require 1 - 2 mg/kg bodyweight propofol for onset of sedation. Maintenance of sedation may be accomplished by titrating Propofol 1% infusion to the desired level of sedation. Most patients require 1.5 - 9 mg/kg/h propofol. The infusion may be supplemented by bolus administration of up to 1 mg/kg bodyweight if a rapid increase of depth of sedation is required.

Propofol 1% must not be given to children and adolescents younger than 16 years of age for sedation in the intensive care unit, since its safety has not been demonstrated in this patient group for this indication.

Method of administration

Propofol 1% is for intravenous use, usually administered on the back of your hand or in the forearm. Your anaesthetist may use a needle or cannula (a fine plastic tube). Propofol 1% will be injected into a vein either manually or by electric pumps. Your doctor will make sure that the pump is compatible with the pre-filled syringes. 10 ml and 20 ml glass syringes and 10 ml plastic syringes are suitable for manual use only and must not be used with a pump.

Propofol 1% is for single use only. Any unused emulsion must be discarded. The pre-filled syringes should be shaken before use. If two layers can be seen after shaking the emulsion should not be used. Use only homogeneous preparations and undamaged pre-filled syringes.

Application of pre-filled syringes (for pre-assembled syringes step 2 can be omitted):

Sterility has to be ensured. The outer surface of the syringe and the plunger rod are not sterile.

  1. 1) Take out the syringe from the packaging and shake it.
  2. 2) Insert the plunger rod by screwing it clock-wise into the syringe.
  3. 3) Remove the tip cap from the syringe and connect the infusion line, needle or cannula to the syringe. Get rid of the air bubble (a small bubble can remain) and the ready-to-use syringe will be installed in the pump or administered manually.

Duration of treatment

When used for sedation, Propofol 1% must not be administered for more than 7 days.

If you received more propofol than you should

Your doctor will ensure that you receive the right amount of propofol for you and for the procedure you are undergoing.

Package leaflet: Information for the user

Product Name:Territory:
  1. 1. Draft
01.08.2023, 14:00Mock up
Propofol 1% MCT PFSUK/IE
  1. 1. Corr
08.08.2023, 07:20
Type of Packaging:Dosage:
  1. 2. Corr
21.08.2023, 07:20
  1. 3. Corr
25.08.2023, 19:00
Leaflet10 ml, 20 ml,50 ml
Material number:2-D-Matrix Code:
M0xxxxx/00 UK/IEM0xxxxx/00 UK/IE
EAN-Code:
Operator:
180 x 882 mmArial9Christina Fraueneder

The emulsion must be drawn aseptically into a giving set immediately after opening the syringe. Administration must commence without delay.

Asepsis must be maintained for both Propofol 1% and the infusion equipment throughout the infusion period. Propofol 1% must not be administered through a microbiological filter.

Infusion of undiluted Propofol 1%:

The use of a burette, drop counter, syringe pump or volumetric infusion pump to control the infusion rate is recommended when Propofol 1% is infused undiluted.

As usual for fat emulsions, the infusion of Propofol 1% via one infusion system must not exceed 12 hours. The infusion set for Propofol 1% must be changed at least every 12 hours.

Infusion of diluted Propofol 1%:

Burettes, drop counters or volumetric infusion pumps should always be used to control infusion rates. The maximum dilution must not exceed 1 part of Propofol 1% with 4 parts of glucose 50 mg/ ml (5 %) solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection (minimum concentration 2 mg propofol per ml). The mixture should be prepared aseptically (controlled and validated conditions preserved) immediately prior to administration and must be administered within 6 hours after preparation.

To reduce pain on the injection site, Propofol 1% should be administered in a larger vein and/or lidocaine injection solution may be administered before induction of anaesthesia with Propofol 1%. Alternatively, lidocaine may be added to the solution (20 parts of Propofol 1% to 1 part of 1% preservative free lidocaine solution for injection) to reduce pain at the site of injection of Propofol 1%.

Intravenous lidocaine must not be used in patients with hereditary acute porphyria.

Muscle relaxants like atracurium and mivacurium should only be administered after flush of the same infusion site used for Propofol 1%.

However, different people need different doses and if you do receive too much for you, your anaesthetist may need to take measures to make sure your heart and breathing are adequately supported. This is why anaesthetic drugs are only administered by doctors trained in anaesthesia or in the care of patients in intensive care.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

Side effects that can happen during anaesthesia

The following side effects can happen during anaesthesia (while the injection is being given to you or when you are sleepy or asleep). Your doctor will be looking out for these. If they happen, your doctor will give you appropriate treatment.

Very common (may affect more than 1 in 10 people)

  • A feeling of pain at the site of the injection (while the injection is being given, before you fall asleep).

Common (may affect up to 1 in 10 people)

  • Slow or fast heartbeat
  • Low blood pressure
  • Changes in your breathing pattern (low respiratory rate, breathing arrest)
  • Hiccups
  • Cough (may also happen when you wake up)

Uncommon (may affect up to 1 in 100 people)

  • Swelling and redness or blood clots at the vein along the injection site.

Rare (may affect up to 1 in 1,000 people)

  • Twitching and shaking of your body, or fits (may also happen when you wake up).

Very rare (may affect up to 1 in 10, 000 people)

  • Serious allergic reaction which causes difficulty in breathing, swollen and reddened skin, hot flushes
  • Build up of fluid in the lungs which can make you very breathless (may also happen when you wake up)
  • Unusual colour of urine (may also happen when you wake up).

Not known (frequency cannot be estimated from the available data)

  • Involuntary movements
  • Severe skin and tissue reaction following accidental application beside the vein.
  • Prolonged, often painful erection (priapism).

Side effects that can happen after anaesthesia

The following side effects can happen after anaesthesia (when you are waking up or after you have woken up).

Common (may affect up to 1 in 10 people)

  • Headache
  • Feeling sick (nausea), being sick (vomiting).
  • Cough.

Rare (may affect up to 1 in 1,000 people)

  • Dizziness, chills and sensations of cold
  • Excitations

Very rare (may affect up to 1 in 10,000 people)

  • Being unconscious after the operation (when this has happened, the patients have recovered without problems)
  • Inflamed pancreas (pancreatitis) which causes severe stomach pain (a causal relationship could not be shown)
  • Fever following surgery

Not known (frequency cannot be estimated from the available data)

  • Feeling euphoric
  • Feeling sexually aroused
  • Irregular heart beat
  • Changes in ECG (Brugada type ECG)
  • Increase in liver size
  • Kidney failure
  • Breakdown of muscle cells (rhabdomyolysis), increase in acidity of your blood, high potassium and fat levels in your blood, heart failure
  • Drug abuse, mostly by healthcare professionals
  • Prolonged, often painful erection (priapism).

When Propofol 1% is administered in combination with lidocaine (a local anaesthetic used to reduce the pain at the site of injection), certain side effects may occur rarely:

  • dizziness
  • vomiting
  • sleepiness
  • fits
  • a slowing of the heart rate (bradycardia)
  • irregular heartbeat (cardiac arrhythmias)
  • shock

Reporting of side effects

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via:

For the UK: Yellow Card Scheme. Website: www. mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.

For Ireland: HPRA Pharmacovigilance. Website:www.hpra.ie.

By reporting side affects you can help provide more information on the safety of this medicine.

5. How to store Propofol 1%

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the syringe and the outer packaging after EXP. The expiry date refers to the last day of that month.

Do not store above 25 °C.

Do not freeze.

After first opening the product must be used immediately.

Administration systems with undiluted Propofol 1% should be replaced 12 hours after opening of the syringe.

Dilutions with glucose 50 mg/ml (5%) solution for injection or sodium chloride 9 mg/ml (0.9%) solution for injection or an admixture with preservative-free lidocaine 10 mg/ml (1%) solution for injection (at least 2 mg propofol per ml) should be prepared aseptically (controlled and validated conditions preserved) immediately before administration and has to be administered within 6 hours after preparation.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Propofol 1% contains

  • The active substance is propofol.

Each ml emulsion contains 10 mg propofol. Each 10 ml syringe contains 100 mg propofol. Each 20 ml syringe contains 200 mg propofol. Each 50 ml syringe contains 500 mg propofol.

  • The other ingredients are soya-bean oil, refined, medium-chain triglycerides, purified egg phosphatides, glycerol, oleic acid, sodium hydroxide, water for injections

What Propofol 1% looks like and contents of the pack

Propofol 1% is a white oil-in-water emulsion for injection/ infusion in a pre-filled syringe.

Propofol 1% is available in plastic and glass pre-filled syringes.

Pack sizes:

Packs containing 5 glass pre-filled syringes with 10 ml emulsion

Packs containing 6 plastic pre-filled syringes with 10 ml emulsion

Packs containing 5 glass pre-filled syringes with 20 ml emulsion

Packs containing 6 plastic pre-filled syringes with 20 ml emulsion

Packs containing 1 plastic pre-filled syringe with 50 ml emulsion

Marketing Authorisation Holder

For UK

Fresenius Kabi Limited

Cestrian Court,

Eastgate Way,

Manor Park,

Runcorn,

Cheshire,

WA7 1NT

UK

For IE

Fresenius Kabi Deutschland GmbH

Else-Kroener Strasse 1,

Bad Homburg v.d.H. 61352,

Germany

Manufacturer:

Fresenius Kabi Austria GmbH

A-8055 Graz, Hafnerstraße 36

Austria

This medicinal product is authorised in the Member States of the EEA under the following names:

Name of the member stateName of the medicinal product
Austria

Propofol „Fresenius" 1 % mit MCT Emulsion zur

Injektion oder Infusion in einer Fertigspritze

BelgiumPropolipid 1 %
Cyprus

Propofol MCT/LCT/ Fresenius 1% (10 mg/ml) γαλάκτωμα για έγχυση ή ένεση σε

προγεμισμένη σύριγγα

DenmarkPropolipid
EstoniaPropoven 1%
GermanyPropofol MCT Fresenius 10 mg/ml Emulsion zur Injektion/Infusion in einer Fertigspritze
Greece

Propofol MCT/LCT/ Fresenius 1% (10 mg/ml) γαλάκτωμα για έγχυση ή ένεση σε

προγεμισμένη σύριγγα

FinlandPropolipid 10 mg/ml injektio-/ infuusioneste, emulsio, esitäytetyssä ruiskussa
HungaryPropofol MCT Fresenius 10 mg/ml emulzió injekcióhoz vagy infúzióhoz előretöltött fecskendőben
IcelandPropolidid 10 mg/ml, stungu- eða innrennslislyf, fleyti í áfylltri sprautu
Ireland

Propofol 1% (10 mg/ml)

emulsion for injection/infusion in pre-filled syringe

ItalyPropofol Kabi
LatviaPropoven 1 % emulsija injekcijām vai infūzijām pilnšļircē
LithuaniaPropoven 1% injekcinė/infuzinė emulsija užpildytame švirkšte
NetherlandsPropofol 10mg/ml MCT/LCT Fresenius
NorwayPropolipid
PolandPropofol 1% MCT/LCT Fresenius
PortugalPropofol 1% MCT/LCT Fresenius
SlovakiaPropofol MCT Fresenius 10 mg/ ml injekčná/infúzna emulzia v naplnenej injekčnej striekačke
SloveniaPropoven 10 mg/ml emulzija za injiciranje/infundiranje v napolnjeni injekcijski brizgi
SpainPropofol Lipoven Fresenius 10 mg/ml emulsión inyectable y para perfusión en jeringa precargada EFG
SwedenPropolipid
United Kingdom

Propofol 1% (10 mg/ml)

emulsion for injection/infusion in pre-filled syringe

This leaflet was last revised in September 2023.

&

About this document

Source: MHRA - Medicines and Healthcare products Regulatory Agency (products.mhra.gov.uk) · Marketing authorisation: PL 08828/0239

Last revision stated in the text: September 2023 · MHRA data as of 13 October 2026

Found a mistake? Tell us on the contact page.

The information on this site does not replace the advice of a doctor or pharmacist.

Facts about Propoven 1% emulsion for injection/infusion in Pre-filled syringe

Prescription needed? Yes, prescription-only medicine (POM)
Active substance Propofol
Strength 1% (10 mg/ml)
Pharmaceutical form Emulsion for injection
pH of emulsion: 7.5 – 8.5
Osmolality of emulsion: 300 mosmol/kg
How is it taken Intravenous
Excipients Soya-bean oil, refined, Medium-chain triglycerides, Purified egg phosphatides, Glycerol, Oleic acid, Sodium hydroxide, Water for injections
Pack sizes 5 ampoule
Is it available? Listed as available (NHS Dictionary of Medicines and Devices – not a record of current supplies)
Shelf life Shelf life of the medicinal product in its original package before opening: 2 years.
Shelf life after first opening: Medicinal product must be used immediately after first opening. Administration systems with undiluted Propofol 1% should be replaced after 12 hours.
Shelf life after dilution: Medicinal product must be used immediately after dilution. The administration should be completed within 6 hours after dilution.
Storage Do not store above 25 °C. Do not freeze.
Drug group (ATC) Anaesthetics; Other general anaesthetics ATC-Code: N01AX10
  1. N Nervous system drugs
    1. N01 Anesthetics
      1. N01A Anesthetics, general
        1. N01AX Other general anesthetics
          1. N01AX10 propofol
Marketing authorisation PL 08828/0239 (first authorised 12 April 2013)
Marketing authorisation holder Fresenius Kabi
Codes BNF 15010100

Sources: the MHRA product information (products.mhra.gov.uk) and the NHS Dictionary of Medicines and Devices (dm+d), release 10.2.0 of 19 October 2026, NHS Business Services Authority. Contains public sector information licensed under the Open Government Licence v3.0.